| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FBL7; CXXC8; FBL11; FBXL11; JHDM1A; LILINA |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human KDM2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KDM2A抗体的3篇参考文献，包含文献名称、作者及简要摘要内容：
---
1. **文献名称**: *Histone demethylation by a family of JmjC domain-containing proteins*
**作者**: Tsukada Y, et al.
**摘要**: 该研究首次报道了KDM2A(当时称为JHDM1A)作为组蛋白H3K36去甲基化酶的活性，并通过特异性抗体验证其在染色质修饰中的作用，揭示了其在表观遗传调控中的关键功能。
2. **文献名称**: *The histone H2A deubiquitinase MYSM1 regulates embryonic stem cell differentiation*
**作者**: He J, et al.
**摘要**: 本文利用KDM2A抗体进行染色质免疫沉淀(ChIP)和Western blot分析，发现KDM2A与干细胞多能性相关基因的调控有关，并参与抑制分化信号通路。
3. **文献名称**: *KDM2A integrates DNA and histone modification signals to regulate transcriptional repression*
**作者**: Farcas AM, et al.
**摘要**: 通过KDM2A抗体进行免疫共沉淀(Co-IP)和功能研究，发现KDM2A与Polycomb复合物协同作用，通过去除H3K36me2标记维持基因沉默状态，影响细胞增殖和分化。
---
以上研究均通过KDM2A抗体在实验(如ChIP、Western blot、Co-IP)中验证其蛋白表达、定位及功能，涵盖表观遗传调控、干细胞分化和癌症相关机制等领域。如需具体抗体来源或实验细节，可进一步查阅原文方法部分。
The KDM2A antibody is a key tool for studying the lysine-specific demethylase 2A (KDM2A), an enzyme involved in epigenetic regulation. KDM2A, also known as FBXL11 or JHDM1A, belongs to the Jumonji C (JmjC) domain-containing histone demethylase family. It specifically demethylates histone H3 on lysine 36 (H3K36me2/me1), modulating chromatin structure and gene expression. KDM2A plays roles in diverse biological processes, including cell proliferation, differentiation, and genomic stability, and is implicated in cancer, stem cell biology, and aging.
The antibody targets KDM2A’s unique domains, such as its JmjC catalytic domain or N-terminal regions, enabling detection and functional analysis in assays like Western blotting, immunofluorescence, or chromatin immunoprecipitation (ChIP). Researchers use it to investigate KDM2A’s interactions with chromatin modifiers (e.g., Polycomb repressive complexes) or its localization to CpG islands, where it may suppress spurious transcription.
Validating KDM2A antibodies requires specificity testing via knockout controls, as cross-reactivity with homologous proteins (e.g., KDM2B) can occur. Commercial antibodies often cite applications in human, mouse, or rat samples. As KDM2A gains attention for its dual roles in tumor suppression and oncogenesis, its antibody remains critical for dissecting context-dependent mechanisms in disease models and therapeutic targeting.
×
